"Huang Medical's pre-market drop exceeds 2%, with Morgan Stanley giving it a 'sell' rating."

Before the market opened, Hua Huang Pharmaceutical fell by 2.58% to $16.6. On the news front, Morgan Stanley analyst Jack Lin issued a "sell" rating on Hua Huang Pharmaceutical with a target price of $13.75.